Clinical Trials Related to Acute Myeloid Leukemia

Related studies linked through entity extraction aliases.

A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia

Status: WITHDRAWN
Phase: PHASE1

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Status: RECRUITING
Phase: PHASE2

HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors

Status: NOT_YET_RECRUITING
Phase: N/A

Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

Status: NOT_YET_RECRUITING
Phase: PHASE2

IFN-α in Relapse Prevention.

Status: NOT_YET_RECRUITING
Phase: PHASE2

Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

Status: NOT_YET_RECRUITING
Phase: PHASE1

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Status: NOT_YET_RECRUITING
Phase: PHASE2

Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia

Status: NOT_YET_RECRUITING
Phase: PHASE1

Venetoclax Combined With Azacitidine for Consolidation Therapy in AML

Status: NOT_YET_RECRUITING
Phase: PHASE2

Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial

Status: RECRUITING
Phase: N/A

Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia

Status: NOT_YET_RECRUITING
Phase: PHASE1

Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax

Status: NOT_YET_RECRUITING
Phase: PHASE3

Motixafortide for MRD Sensitization in AML

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

Status: RECRUITING
Phase: PHASE2

Effect of Hypnosis and Virtual Reality on Anxiety During Treatment for Acute Myeloid Leukemia

Status: NOT_YET_RECRUITING
Phase: NA

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

Status: RECRUITING
Phase: PHASE1

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

Status: RECRUITING
Phase: PHASE1

GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia

Status: NOT_YET_RECRUITING
Phase: PHASE1/PHASE2

A Study of Revumenib and Mezigdomide in People With Leukemia

Status: RECRUITING
Phase: PHASE1/PHASE2